Renal Mechanism of Action/Splay vs. TmG

Stopped early · Phase 1

Conditions studied: Diabetes, NOS

In brief

The purpose of this study is to evaluate the effects of dapagliflozin to promote glucose loss in urine in healthy subjects and subjects with type 2 diabetes mellitus

Key facts

Study ID

NCT00726505

Run by

AstraZeneca

People needed

1

Starts

2009-06-01

Expected to finish

2009-08-01

Last updated by the study team

2016-10-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male and female subjects
• Age 18 to 65 years
• BMI 18 to 35 kg/m2
• Healthy subjects and subjects with type 2 diabetes mellitus on 1 of the following therapies: diet, sulfonylurea, and/or metformin
• No evidence of impaired renal function

You may not qualify if…

• Unwilling or unable to use an acceptable method of birth control
• Subjects with type 1 diabetes mellitus, heart disease, hepatic C or B
• Exposure to insulin
• Use of exclusionary concomitant medications
• Evidence of significant kidney disease or any other significant medical or psychiatric disorder

Where it is running

• University Of Texas Health Center At San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.